Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19

References

• Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1):93–97.
   PubMed Web of Science ®Google Scholar
• Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518.
   PubMed Web of Science ®Google Scholar
• Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.
   PubMed Web of Science ®Google Scholar
• Brechot N, Hekimian G, Chastre J, et al. Procalcitonin to guide antibiotic therapy in the ICU. Int J Antimicrob Agents. 2015;46 (Suppl 1):S19–S24.
   PubMedGoogle Scholar
• Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. Pharmacotherapy. 2018;38(5):569–581.
   PubMed Web of Science ®Google Scholar
• Cleland DA, Eranki AP. Procalcitonin. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Karzai W, Oberhoffer M, Meier-Hellmann A, et al. Procalcitonin–a new indicator of the systemic response to severe infections. Infection. 1997;25(6):329–334.
   PubMed Web of Science ®Google Scholar
• Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250–1256.
   PubMed Web of Science ®Google Scholar
• Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med. 1998;24(2):185–188.
   PubMed Web of Science ®Google Scholar
• Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680–684.
   PubMed Web of Science ®Google Scholar
• Carsin H, Assicol M, Feger F, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury. Burns. 1997;23(3):218–224.
   PubMed Web of Science ®Google Scholar
• Attar BM, Moore CM, George M, et al. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. WJG. 2014;20(9):2374–2382.
   PubMed Web of Science ®Google Scholar
• Leppaniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.
   PubMed Web of Science ®Google Scholar
• El-Solh AA, Vora H, Knight PR III, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med. 2011;39:1251–1256.
   PubMed Web of Science ®Google Scholar
• Turner D, Hammerman C, Rudensky B, et al. Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Arch Dis Child Fetal Neonatal Ed. 2006;91(4):F283–F286.
   PubMed Web of Science ®Google Scholar
• Eschborn S, Weitkamp JH. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. J Perinatol. 2019;39(7):893–903.
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–5584.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva (Switzerland): World Health Organization; 2014.
   Google Scholar
• Paudel R, Dogra P, Montgomery-Yates AA, et al. Procalcitonin: a promising tool or just another overhyped test? Int J Med Sci. 2020;17(3):332–337.
   PubMed Web of Science ®Google Scholar
• Peng F, Chang W, Xie JF, et al. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: a meta-analysis. Int J Infect Dis. 2019;85:158–166.
   PubMed Web of Science ®Google Scholar
• Taylor R, Jones A, Kelly S, et al. A review of the value of procalcitonin as a marker of infection. Cureus. 2017;9(4):e1148.
   PubMed Web of Science ®Google Scholar
• An PJ, Zhu YZ, Yang LP. Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. Pharmacol Res. 2020;159:104946.
   PubMed Web of Science ®Google Scholar
• So-Ngern A, Leelasupasri S, Chulavatnatol S, et al. Prognostic value of serum procalcitonin level for the diagnosis of bacterial infections in critically-ill patients. Infect Chemother. 2019;51(3):263–273.
   PubMed Web of Science ®Google Scholar
• van Berkel M, Kox M, Frenzel T, et al. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care. 2020;24(1):600.
   PubMed Web of Science ®Google Scholar
• Shafiq N, Gautam V, Pandey AK, et al. A meta-analysis to assess usefulness of procalcitonin-guided antibiotic usage for decision making. Indian J Med Res. 2017;146:576–584.
   PubMed Web of Science ®Google Scholar
• Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe. 2019;15(4):296–304.
   Web of Science ®Google Scholar
• Lin C, Pang Q. Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12(1):10–15.
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26:160073.
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012;38(6):940–949.
   PubMed Web of Science ®Google Scholar
• McDonagh MS, Peterson K, Winthrop K, et al. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018;46(8):3337–3357.
   PubMed Web of Science ®Google Scholar
• Meier MA, Branche A, Neeser OL, et al. Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis. 2019;69(3):388–396.
   PubMed Web of Science ®Google Scholar
• Oppert M. [Diagnosis of sepsis and guidance of antibiotic therapy]. Med Klin Intensivmed Notfmed. 2019;114(4):286–289.
   PubMed Web of Science ®Google Scholar
• Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock–a systematic review and meta-analysis. Crit Care. 2013;17(6):R291.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651–662.
   PubMed Web of Science ®Google Scholar
• Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390(10097):871–881.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang Y, Yang Q, et al. Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis. BMC Infect Dis. 2017;17(1):514.
   PubMedGoogle Scholar
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827.
   PubMed Web of Science ®Google Scholar
• Huang HB, Peng JM, Weng L, et al. Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. Ann Intensive Care. 2017;7(1):114.
   PubMedGoogle Scholar
• Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-Guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019;155(6):1109–1118.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level Meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.
   PubMedGoogle Scholar
• Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level Meta-analysis of randomized trials. Crit Care. 2018;22(1):191.
   PubMedGoogle Scholar
• Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15(1):15.
   PubMed Web of Science ®Google Scholar
• Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLOS One. 2018;13(11):e0206527.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li C, Jia Y. Evaluation of the mortality in emergency department sepsis score combined with procalcitonin in septic patients. Am J Emerg Med. 2013;31(7):1086–1091.
   PubMed Web of Science ®Google Scholar
• Li H, Luo YF, Blackwell TS, et al. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother. 2011;55(12):5900–5906.
   PubMed Web of Science ®Google Scholar
• Nunnally ME, Patel A. Sepsis – what's new in 2019? Curr Opin Anaesthesiol. 2019;32(2):163–168.
   PubMed Web of Science ®Google Scholar
• Pugh R, Grant C, Cooke RP, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577.
   PubMed Web of Science ®Google Scholar
• Vouloumanou EK, Plessa E, Karageorgopoulos DE, Mantadakis E, et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med. 2011;37(5):747–762.
   PubMed Web of Science ®Google Scholar
• van der Does Y, Limper M, Jie KE, Schuit SCE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 2018;24(12):1282–1289.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308–1318.
   PubMed Web of Science ®Google Scholar
• Tonkin-Crine SK, Tan PS, van Hecke O, et al. Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. Cochrane Database Syst Rev. 2017;(9):CD012252.
   PubMedGoogle Scholar
• Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–217.
   PubMed Web of Science ®Google Scholar
• Dilger AE, Peters AT, Wunderink RG, et al. Procalcitonin as a biomarker in rhinosinusitis: a systematic review. Am J Rhinol Allergy. 2019;33(2):103–112.
   PubMed Web of Science ®Google Scholar
• Lhopitallier L, Kronenberg A, Meuwly JY, et al. Procalcitonin and lung ultrasonography point-of-care testing to decide on antibiotic prescription in patients with lower respiratory tract infection in primary care: protocol of a pragmatic cluster randomized trial. BMC Pulm Med. 2019;19(1):143.
   PubMed Web of Science ®Google Scholar
• van der Does Y, Rood PP, Haagsma JA, et al. Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review. Am J Emerg Med. 2016;34(7):1286–1293.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: Results from the multicenter procalcitonin MOnitoring SEpsis (MOSES) study. Crit Care Med. 2017;45(5):781–789.
   PubMed Web of Science ®Google Scholar
• Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev. 2017;38(2):59–68.
   PubMedGoogle Scholar
• Downes KJ, Fitzgerald JC, Weiss SL. Utility of procalcitonin as a biomarker for sepsis in children. J Clin Microbiol. 2020;58(7):e01851-19.
   PubMed Web of Science ®Google Scholar
• Rhee C. Using procalcitonin to guide antibiotic therapy. Open Forum Infect Dis. 2017;4:ofw249.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021;203(2):202–210.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066.
   PubMed Web of Science ®Google Scholar
• Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia–a systematic review. Dan Med J. 2012;59(3):A4357.
   PubMed Web of Science ®Google Scholar
• Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542.
   PubMed Web of Science ®Google Scholar
• Montassier E, Javaudin F, Moustafa F, et al. Guideline-Based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a pragmatic randomized trial. Ann Emerg Med. 2019;74(4):580–591.
   PubMed Web of Science ®Google Scholar
• Wussler D, Kozhuharov N, Tavares Oliveira M, et al. Clinical utility of procalcitonin in the diagnosis of pneumonia. Clin Chem. 2019;65(12):1532–1542.
   PubMed Web of Science ®Google Scholar
• Kaziani K, Sotiriou A, Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers. Curr Opin Infect Dis. 2017;30(2):221–225.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017;50:1700582.
   PubMed Web of Science ®Google Scholar
• Chen K, Pleasants KA, Pleasants RA, et al. Procalcitonin for antibiotic prescription in chronic obstructive pulmonary disease exacerbations: systematic review, meta-analysis, and clinical perspective. Pulm Ther. 2020;6(2):201–214.
   PubMedGoogle Scholar
• Li Z, Yuan X, Yu L, et al. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: an updated meta-analysis. Medicine. 2019;98(32):e16775.
   PubMed Web of Science ®Google Scholar
• Hui DS, EI, Madani TA, Ntoumi F, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
   PubMed Web of Science ®Google Scholar
• Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402.
   PubMed Web of Science ®Google Scholar
• Stegeman I, Ochodo EA, Guleid F, et al. Routine laboratory testing to determine if a patient has COVID-19. Cochrane Database Syst Rev. 2020;11:CD013787.
   PubMedGoogle Scholar
• Nazerian P, Gagliano M, Suardi LR, et al. Procalcitonin for the differential diagnosis of COVID-19 in the emergency department. Prospective monocentric study. Intern Emerg Med. 2021;16(6):1733–1735.
   PubMed Web of Science ®Google Scholar
• Del Sole F, Farcomeni A, Loffredo L, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378.
   PubMed Web of Science ®Google Scholar
• Elshazli RM, Toraih EA, Elgaml A, El-Mowafy M, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a Meta-analysis of 6320 patients. PLOS One. 2020;15(8):e0238160.
   PubMed Web of Science ®Google Scholar
• Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362.
   PubMed Web of Science ®Google Scholar
• Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
   Web of Science ®Google Scholar
• Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLOS One. 2020;15(11):e0241955.
   PubMed Web of Science ®Google Scholar
• Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine. 2020;99(47):e23315.
   PubMed Web of Science ®Google Scholar
• Krause M, Douin DJ, Tran TT, et al. Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients. PLOS One. 2020;15(9):e0239174.
   PubMed Web of Science ®Google Scholar
• Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2020;26(3):107–108.
   PubMedGoogle Scholar
• Mudatsir M, Fajar JK, Wulandari L, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Res. 2020;9:1107.
   PubMedGoogle Scholar
• Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399.
   PubMed Web of Science ®Google Scholar
• Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–1474.
   PubMed Web of Science ®Google Scholar
• Yang L, Jin J, Luo W, et al. Risk factors for predicting mortality of COVID-19 patients: a systematic review and meta-analysis. PLOS One. 2020;15(11):e0243124.
   PubMed Web of Science ®Google Scholar
• Zare ME, Wang Y, N, Kansestani A, et al. Procalcitonin has good accuracy for prognosis of critical condition and mortality in COVID-19: a diagnostic test accuracy systematic review and Meta-analysis. Iran J Allergy Asthma Immunol. 2020;19:557–569.
   PubMed Web of Science ®Google Scholar
• Zhang JJY, Lee KS, Ang LW, et al. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199–2206.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Japar KV, Kwenandar F, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis. Am J Emerg Med. 2021;41:110–119.
   PubMed Web of Science ®Google Scholar
• Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. Am J Emerg Med. 2021;46:525–531.
   PubMed Web of Science ®Google Scholar
• Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459–2468.
   PubMed Web of Science ®Google Scholar
• Vaughn VM, Gandhi T, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis. 2020;72(10):e533–e541.
   Web of Science ®Google Scholar
• Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Med. 2020;46(11):2071–2074.
   PubMed Web of Science ®Google Scholar
• Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10(1):119.
   PubMed Web of Science ®Google Scholar
• Zhou YZ, Teng XB, Han MF, et al. The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19. Eur Rev Med Pharmacol Sci. 2021;25:1097–1100.
   PubMed Web of Science ®Google Scholar
• Napoli C, Benincasa G, Criscuolo C, et al. Immune reactivity during COVID-19: Implications for treatment. Immunol Lett. 2021;231:28–34.
   PubMed Web of Science ®Google Scholar
• Asoglu R, Tibilli H, Afsin A, Turkmen S, et al. Procalcitonin is a predictor of disseminated intravascular coagulation in patients with fatal COVID-19. Eur Rev Med Pharmacol Sci. 2020;24:11953–11959.
   PubMed Web of Science ®Google Scholar
• Ashiru-Oredope D, Kerr F, Hughes S, et al. Assessing the impact of COVID-19 on antimicrobial stewardship activities/programs in the United Kingdom. Antibiotics. 2021;10:110.
   Google Scholar
• Heesom L, Rehnberg L, Nasim-Mohi M, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist. 2020;22:782–784.
   PubMed Web of Science ®Google Scholar
• Peters C, Williams K, Un EA, et al. Use of procalcitonin for antibiotic stewardship in patients with COVID-19: a quality improvement project in a district general hospital. Clin Med. 2021;21(1):e71–e76.
   PubMed Web of Science ®Google Scholar
• Pulia MS, Wolf I, Schwei RJ, et al. Antibiotic prescribing patterns for coronavirus disease 2019 (COVID-19) in two emergency departments with rapid procalcitonin. Infect Control Hosp Epidemiol. 2021;42(3):359–353.
   PubMed Web of Science ®Google Scholar
• Williams EJ, Mair L, de Silva TI, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp Infect. 2021;110:103–107.
   PubMed Web of Science ®Google Scholar
• Velissaris D, Pintea M, Pantzaris N, et al. The role of procalcitonin in the diagnosis of meningitis: a literature review. J Clin Med. 2018;7:148.
   Web of Science ®Google Scholar
• Chaudhary S, Bhatta NK, Lamsal M, et al. Serum procalcitonin in bacterial & non-bacterial meningitis in children. BMC Pediatr. 2018;18(1):342.
   PubMedGoogle Scholar
• Pescatore R, Niforatos JD, Rezaie S, et al. Evidence-informed practice: diagnostic questions in urinary tract infections in the elderly. West J Emerg Med. 2019;20(4):573–577.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014;175(3):464–472.
   PubMed Web of Science ®Google Scholar
• Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (biomarkers in acute heart failure) trial. Eur J Heart Fail. 2012;14(3):278–286.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol. 2016;223:390–397.
   PubMed Web of Science ®Google Scholar
• Ibrahim WH, Mushtaq K, Raza T, et al. Effects of procalcitonin-guided treatment on antibiotic use and need for mechanical ventilation in patients with acute asthma exacerbation: meta-analysis of randomized controlled trials. Int J Infect Dis. 2017;65:75–80.
   PubMed Web of Science ®Google Scholar
• Thwaites CL, Lundeg G, Dondorp AM, et al. Infection management in patients with sepsis and septic shock in resource-limited settings. In: Dondorp AM, Dunser MW, Schultz MJ, editors. Sepsis management in resource-limited settings. Geneva (Switzerland): Cham; 2019. p. 163–184.
   Google Scholar
• van Griensven J, Cnops L, De Weggheleire A, et al. Point-of-care biomarkers to guide antibiotic prescription for acute febrile illness in sub-Saharan Africa: promises and caveats. Open Forum Infect Dis. 2020;7(8):ofaa260.
   PubMed Web of Science ®Google Scholar
• Daubin C, Valette X, Thiolliere F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med. 2018;44(4):428–437.
   PubMed Web of Science ®Google Scholar
• Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018;46(5):684–690.
   PubMed Web of Science ®Google Scholar
• Lam SW, Bauer SR, Duggal A. Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: is it time to rethink our strategy? Int J Antimicrob Agents. 2016;47(1):20–27.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Thompson-Leduc P, Kirson NY, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis. Crit Care Med. 2018;46:691–698.
   PubMed Web of Science ®Google Scholar
• Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. J Korean Med Sci. 2019;34(14):e110.
   PubMed Web of Science ®Google Scholar
• Gregoriano C, Heilmann E, Molitor A, et al. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020;12(Suppl 1):S5–S15.
   PubMedGoogle Scholar
• Azzini AM, Dorizzi RM, Sette P, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the evidence based laboratory medicine. Ann Transl Med. 2020;8(9):610.
   PubMed Web of Science ®Google Scholar
• Madershahian N, Wittwer T, Strauch J, et al. Kinetic of procalcitonin in the early postoperative course following heart transplantation. J Card Surg. 2008;23(5):468–473.
   PubMed Web of Science ®Google Scholar
• Kaido T, Ogawa K, Fujimoto Y, et al. Perioperative changes of procalcitonin levels in patients undergoing liver transplantation. Transpl Infect Dis. 2014;16(5):790–796.
   PubMed Web of Science ®Google Scholar
• Varetto G, Castagno C, Trucco A, et al. Serum procalcitonin as a valuable diagnostic tool in the early detection of infectious complications after open abdominal aortic repair. Ann Vasc Surg. 2016;34:111–118.
   PubMed Web of Science ®Google Scholar
• Liu H, Luo Z, Liu L, et al. Early kinetics of procalcitonin in predicting surgical outcomes in type A aortic dissection patients. Chin Med J. 2017;130(10):1175–1181.
   PubMed Web of Science ®Google Scholar
• Amin DN, Pruitt JC, Schuetz P. Influence of major cardiopulmonary surgery on serum levels of procalcitonin and other inflammatory markers. Anaesth Intensive Care. 2012;40(5):760–766.
   PubMed Web of Science ®Google Scholar
• Bouaicha S, Blatter S, Moor BK, et al. Early serum procalcitonin level after primary total hip replacement. Mediators Inflamm. 2013;2013:927636.
   PubMed Web of Science ®Google Scholar
• Yoon JR, Yang SH, Shin YS. Diagnostic accuracy of interleukin-6 and procalcitonin in patients with periprosthetic joint infection: a systematic review and meta-analysis. Int Orthop. 2018;42(6):1213–1226.
   PubMed Web of Science ®Google Scholar
• Jiang N, Ma YF, Jiang Y, et al. Clinical characteristics and treatment of extremity chronic osteomyelitis in Southern China: a retrospective analysis of 394 consecutive patients. Medicine. 2015;94(42):e1874.
   PubMed Web of Science ®Google Scholar
• Assumma M, Signore F, Pacifico L, et al. Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study. Clin Chem. 2000;46(10):1583–1587.
   PubMed Web of Science ®Google Scholar
• Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998;26(3):664–672.
   PubMed Web of Science ®Google Scholar
• Pontrelli G, De Crescenzo F, Buzzetti R, et al. Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis. BMC Infect Dis. 2017;17(1):302.
   PubMedGoogle Scholar
• Stocker M, van Herk W, El Helou S, Dutta S, et al. C-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study. Clin Infect Dis. 2020;73(2):e383–e390.
   Web of Science ®Google Scholar
• Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr. 2016;170(1):62–69.
   PubMed Web of Science ®Google Scholar
• Bobillo-Perez S, Rodríguez-Fanjul J, Jordan Garcia I. Is procalcitonin useful in pediatric critical care patients? Biomark Insights. 2018;13:1177271918792244.
   Web of Science ®Google Scholar
• Alejandre C, Guitart C, Balaguer M, et al. Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis. Eur J Pediatr. 2021;180(3):833–842.
   PubMed Web of Science ®Google Scholar
• Hamade B, Huang DT. Procalcitonin: where are we now? Crit Care Clin. 2020;36(1):23–40.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Bretscher C, Bernasconi L, et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev Mol Diagn. 2017;17(6):593–601.
   PubMed Web of Science ®Google Scholar